Enzymatica AB (publ) (ENZY.ST)
SEK 1.68
(-1.18%)
SEK 1.68
(-1.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 26.1 Million SEK | 16.98% |
| 2022 | 22.31 Million SEK | 757.94% |
| 2021 | 2.6 Million SEK | -82.03% |
| 2020 | 14.47 Million SEK | 143.09% |
| 2019 | 5.95 Million SEK | 24.49% |
| 2018 | 4.78 Million SEK | -42.48% |
| 2017 | 8.31 Million SEK | 18.77% |
| 2016 | 7 Million SEK | -36.01% |
| 2015 | 10.93 Million SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 192 Thousand SEK | 0.0% |
| 2009 | 1.89 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 27.17 Million SEK | -2.98% |
| 2024 Q1 | 28 Million SEK | 7.29% |
| 2023 Q2 | 22.65 Million SEK | 0.81% |
| 2023 Q1 | 22.46 Million SEK | 0.68% |
| 2023 FY | 26.1 Million SEK | 16.98% |
| 2023 Q4 | 26.1 Million SEK | 1.77% |
| 2023 Q3 | 25.64 Million SEK | 13.24% |
| 2022 Q4 | 22.31 Million SEK | 1607.35% |
| 2022 Q1 | 2.7 Million SEK | 3.81% |
| 2022 FY | 22.31 Million SEK | 757.94% |
| 2022 Q3 | 1.3 Million SEK | -39.18% |
| 2022 Q2 | 2.14 Million SEK | -20.41% |
| 2021 FY | 2.6 Million SEK | -82.03% |
| 2021 Q4 | 2.6 Million SEK | -79.78% |
| 2021 Q2 | 13.35 Million SEK | -7.51% |
| 2021 Q1 | 14.44 Million SEK | -0.21% |
| 2021 Q3 | 12.86 Million SEK | -3.7% |
| 2020 Q2 | 12.49 Million SEK | -20.54% |
| 2020 Q3 | 14.91 Million SEK | 19.39% |
| 2020 Q4 | 14.47 Million SEK | -2.98% |
| 2020 FY | 14.47 Million SEK | 143.09% |
| 2020 Q1 | 15.72 Million SEK | 164.12% |
| 2019 FY | 5.95 Million SEK | 24.49% |
| 2019 Q1 | 6.28 Million SEK | 31.39% |
| 2019 Q2 | 5.64 Million SEK | -10.19% |
| 2019 Q3 | 5.08 Million SEK | -9.96% |
| 2019 Q4 | 5.95 Million SEK | 17.16% |
| 2018 Q1 | 7.05 Million SEK | -15.16% |
| 2018 FY | 4.78 Million SEK | -42.48% |
| 2018 Q3 | 37.67 Million SEK | 97.02% |
| 2018 Q2 | 19.12 Million SEK | 171.05% |
| 2018 Q4 | 4.78 Million SEK | -87.31% |
| 2017 Q3 | 7.76 Million SEK | -6.61% |
| 2017 Q1 | 1.7 Million SEK | -75.63% |
| 2017 Q4 | 8.31 Million SEK | 7.14% |
| 2017 FY | 8.31 Million SEK | 18.77% |
| 2017 Q2 | 8.3 Million SEK | 387.05% |
| 2016 Q4 | 7 Million SEK | 20.59% |
| 2016 FY | 7 Million SEK | -36.01% |
| 2016 Q2 | 11.48 Million SEK | -41.58% |
| 2016 Q3 | 5.8 Million SEK | -49.44% |
| 2016 Q1 | 19.65 Million SEK | 79.65% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q4 | 10.93 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | 10.93 Million SEK | 0.0% |
| 2014 Q2 | - SEK | -100.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q1 | 214 Thousand SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q2 | 341.39 Thousand SEK | -27.37% |
| 2012 Q3 | 254.92 Thousand SEK | -25.33% |
| 2012 Q1 | 470.06 Thousand SEK | 0.0% |
| 2012 Q4 | - SEK | -100.0% |
| 2012 FY | - SEK | -100.0% |
| 2011 FY | 192 Thousand SEK | 0.0% |
| 2011 Q3 | 579.92 Thousand SEK | -13.67% |
| 2011 Q2 | 671.76 Thousand SEK | 0.0% |
| 2009 FY | 1.89 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | -196.625% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -5886.927% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | -37.878% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -451.045% |
| Nanexa AB (publ) | 4.03 Million SEK | -547.396% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 94.491% |
| Probi AB (publ) | 53.79 Million SEK | 51.479% |
| Swedencare AB (publ) | 1.65 Billion SEK | 98.426% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.873% |
| Toleranzia AB | 850 Thousand SEK | -2970.941% |
| Vivesto AB | 8.16 Million SEK | -219.576% |